Evaluation of Gut Permeability in Patients Affected by Obesity and NAFLD: Influence of Ketogenic Diet.

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-65
SponsorAzienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis

About this trial

This study is open label, with one arm only. In this study will be enrolled patients with obesity (BMI more than 30). Aim of the study is to determine the influence (if any) of a very low calorie ketogenic diet (VLCKD) on gut permeability and liver steatosis.

The first objective is to examine the influence of obesity on the prevalence and severity of impaired intestinal permeability and hepatic steatosis.

Intestinal permeability means the ability of the intestinal barrier to block the passage of substances potentially harmful to our body.

The second objective is to evaluate whether a low-calorie and ketogenic dietary intervention, lasting 6 weeks, can change intestinal permeability and hepatic steatosis

Eligibility criteria

Qualifiers

BMI ≥ 30 Kg/m2 or abdominal circumference (waist) >94 cm in men and >80 cm in women (IDF criteria for the definition of abdominal obesity) with or without the features that characterize the metabolic syndrome

Age range between 18 and 70 years, both sexes

Diagnosis of hepatic steatosis, formulated on the basis of fibroscan [CAP (controlled attenuation parameter) > 238 dB/m(decibel/meter)], and other recognized criteria (FLI - Fatty Liver Index , FIB-4 - Fibrosis-4 index, NFS - NAFLD fibrosis score).

Disqualifiers

Normal and underweight subjects

Presence of any pathology that may affect the presence of altered intestinal permeability or steatosis, apart from pathologies that represent inclusion criteria

Treatment with any device, pharmacological or not, that can affect intestinal permeability and liver metabolism and, therefore, the presence of steatosis

Pregnancy or lactation

Trial design

Treatments tested in this trial

  • Ketogenic Diet

Treatment groups

30 Participants
are divided into 1 treatment group

Sponsors and collaborators

Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis

Lead sponsor

Francesco Russo

Collaborator

Giuseppe, Riezzo

Collaborator

Michele, Linsalata

Collaborator

Antonella, Orlando

Collaborator

Benedetta, D Attoma

Collaborator

Laura, Prospero

Collaborator

Antonia, Ignazzi

Collaborator

Sara, De Nucci

Collaborator

Raffaele, Cozzolongo

Collaborator

Vito, Giannuzzi

Collaborator

Maria, De Angelis

Collaborator

Giusy Rita, Caponio

Collaborator

Oronzo, Milella

Collaborator

Gianluigi, Giannelli

Collaborator